The Future of Ketamine and Mood Disorders In 2019, the FDA and European Commission authorized the usage of an esketamine nasal spready beneath the model title Spravato to treat depression. Nonetheless, as of 2021, ketamine has not been accredited with the FDA to deal with depression or other mental health disorders, and as a consequence, the medica